June Sherie Almenoff - 10 Dec 2021 Form 4 Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Role: Director
Signature: /s/ June Sherie Almenoff
Issuer symbol: BCLI
Transactions as of: 10 Dec 2021
Net transactions value: $0
Form type: 4
Filing time: 10 Dec 2021, 19:00:45 UTC
Previous filing: 12 Nov 2021
Next filing: 17 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BCLI	Common Stock	Award	$0	+2,000	+100%	$0.000000	4,000	10 Dec 2021	Direct	F1
holding	BCLI	Common Stock						7,175	10 Dec 2021	By Meadowlark Management LLC	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares acquired are shares of restricted stock awarded in connection with the Company's 2020 Annual Meeting of Stockholders pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vested in 12 consecutive, equal monthly installments commencing on December 11, 2020 until fully vested on the first anniversary of November 11, 2020, provided that the reporting person remained a director (and committee member, as applicable) of Brainstorm Cell Therapeutics on each vesting date.
F2	The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for the purposes of Section 16 or for any other purpose.

Content

Shares acquired are shares of restricted stock awarded in connection with the Company's 2020 Annual Meeting of Stockholders pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vested in 12 consecutive, equal monthly installments commencing on December 11, 2020 until fully vested on the first anniversary of November 11, 2020, provided that the reporting person remained a director (and committee member, as applicable) of Brainstorm Cell Therapeutics on each vesting date.

The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for the purposes of Section 16 or for any other purpose.